We've detected you are on Internet Explorer. For the best Barrons.com experience, please update to a modern browser.GoogleFirefox
Sign In

This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.

https://www.barrons.com/articles/voyager-therapeutics-stock-pfizer-51633524712

Voyager Therapeutics Stock Had Been Beaten Down. Here’s Why It’s Soaring.

By
Josh Nathan-Kazis
  • Order Reprints
  • Print Article

Shares of a small biotech called Voyager Therapeutics jumped 46% on Wednesday after the company said Pfizer had licensed access to its gene therapy technology in a deal worth up to $630 million.

According to Voyager (ticker: VYGR), Pfizer will pay $30 million up front for options to use proteins known as capsids developed by Voyager in its gene therapy programs. The capsids are shells that coat the viruses used to deliver genetic material as part of gene therapy. Voyager’s technology identifies capsids designed to more effectively...

Copyright ©2021 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.